RECOMBINANT ANTIBODIES AS INTRA VAGINAL SPERMICIDES

重组抗体作为阴道内杀精剂

• 批准号: 2421477
• 负责人: ALAN B DIEKMAN
• 金额: $ 8.8万
• 依托单位: CONTRAVAC, INC.
• 依托单位国家: 美国
• 财政年份: 1997
• 资助国家: 美国
• 起止时间: 1997-09-29 至 1999-09-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/2421477
• 关键词: contraceptives; drug design /synthesis /production; fertility immunology; method development; molecular cloning; monoclonal antibody; recombinant proteins; spermicide; transfection

World population is predicted to reach 10 billion people by the year 2050, increasing more than 75% over the current population. Development of new contraceptive options is necessary to provide accessible birth control to all individuals regardless of sociological, financial, or educational limitations. Current literature implicates marketed spermicidal formulations in cervical and vaginal irritation leading to lesions and acquisition of sexually transmitted diseases. Reassessment of these spermicides by the FDA may result in increased costs or their removal from the market. New, inexpensive spermicides with improved safety and effectiveness must be developed. The objective of this research proposal is the development of a spermicide based on an anti-sperm monoclonal antibody, S19. This mAb inhibits human sperm function and gamete interactions in vitro. The proposed Phase l study will test the feasibility of expressing and purifying sufficient quantities of biologically active recombinant S19 antibody. Towards the expression of a recombinant S19 antibody, the S19 heavy and light chain variable regions were cloned and sequenced. The specific aims of this research proposal are to express recombinant S19 antibody and evaluate the antigen-binding activity of the recombinant antibody. The proposed research will provide a model for anti-sperm antibody immunocontraceptives. PROPOSED COMMERCIAL APPLICATIONS The S19 mAb inhibits human sperm function and gamete interactions and is therefore an attractive candidate for the development of an antibody-based, intravaginal spermicide. The proposed studies will examine recombinant S19 ScFv to determine its feasibility as an inexpensive source of the S19 antibody.

预计到2019年，世界人口将达到100亿 2050年，比目前人口增加75%以上。 开发新的避孕选择是必要的，以提供 所有个人都可以获得节育措施，无论 社会、经济或教育方面的限制。当前 文献表明，市场上销售的杀精子配方在宫颈 和阴道刺激导致病变和获得性 性传播疾病。对这些杀精剂的重新评估 FDA可能会导致成本增加或将其从 市场。新型廉价杀精剂具有更高的安全性和 必须提高有效性。这项研究的目的是 建议开发一种基于抗精子的杀精剂 单抗，S19。该单抗可抑制人类精子功能 和配子在体外的相互作用。拟议的L阶段研究将 测试充分表达和纯化的可行性 获得具有生物活性的重组S19抗体。朝向 重组S19抗体S19 Heavy和S19的表达 对轻链可变区进行克隆和测序。这个 本研究提案的具体目的是表达重组人 S19抗体，并评价其抗原结合活性。 重组抗体。拟议的研究将提供一个模型 用于抗精子抗体免疫避孕药。 S19单抗抑制人类精子的拟议商业应用 功能和配子相互作用，因此是一个有吸引力的 一种以抗体为基础的阴道内注射的候选药物 杀精剂。拟议的研究将检查重组S19单链抗体 以确定其作为S19廉价来源的可行性 抗体。